(Reuters) - GE said it would buy Abbott's primary in-vitro diagnostics, which involve routine laboratory tests, and its Point-of-Care diagnostics business -- tests done typically at a patient's bedside such as blood chemistry work.
Abbott's more profitable molecular diagnostics business, including sophisticated tests for bladder cancer and susceptibility to breast cancer, and its lucrative diabetes-care businesses, are not part of the transaction.
Read more at Reuters.com Government Filings News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment